Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

In a report released yesterday, Mark Lipacis from Evercore ISI maintained a Hold rating on Qualcomm (QCOM – Research Report), with a price ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Stay updated on the latest stock market trends and company earnings. Discover the impact of market gains and profit reports ...

U.S. stock futures are edging mostly higher as market participants focus on tech stocks and corporate earnings; Honeywell announces a split of its automation, aerospace, and advan ...

In this article, we are going to take a look at where QUALCOMM Incorporated (NASDAQ:QCOM) stands against other best socially responsible stocks to buy according to hedge funds. Socially responsible ...

Madison Investments highlighted QCOM in its Q3 2024 investor letter. Here is what the firm has to say: “Alphabet Inc., Eli Lilly and Company, QUALCOMM Incorporated (NASDAQ:QCOM), Microsoft ...

Solbinsiran sodium is under clinical development by Eli Lilly and Co and currently in Phase II for Mixed Dyslipidemia. According to GlobalData, Phase II drugs for Mixed Dyslipidemia have a 74% phase ...